Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLOHA-2
NCT05473910Phase 1Active, not recruiting
- Sponsor
- TScan Therapeutics
- Start
- Nov 2022
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSC-100 and TSC-101 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL) (3 arms), sponsored by TScan Therapeutics. Primary endpoints: Dose Limiting Toxicities at 2 years and Adverse Events at 2 years. Started Nov 2022; status: active, not recruiting.
02
Drugs
TSC-100TSC-101
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05473910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473910.